A phase I study of continuous infusion cilengitide in patients with solid tumors

@article{ODonnell2010API,
  title={A phase I study of continuous infusion cilengitide in patients with solid tumors},
  author={Peter H. O’Donnell and Samir D. Undevia and Walter M. Stadler and Theodore M. Karrison and Martin Kelly Nicholas and Linda Janisch and Mark J. Ratain},
  journal={Investigational New Drugs},
  year={2010},
  volume={30},
  pages={604-610}
}
Background: Cilengitide (EMD121974) is a cyclized pentapeptide that is a potent and selective integrin antagonist which has shown activity in malignant gliomas. In all previous studies, cilengitide has been administered in an intermittent fashion. However, cilengitide has a short half-life of 3–5 h with no evidence of drug accumulation. These data prompted the initiation of this phase I study of continuous infusion cilengitide. Methods: Cilengitide was administered as a continuous infusion… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 14 references

Similar Papers

Loading similar papers…